Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications by Lowes, Lori E. et al.
Western University
Scholarship@Western
Anatomy and Cell Biology Publications Anatomy and Cell Biology Department
2-2014
Adaptation of Semiautomated Circulating Tumor
Cell (CTC) Assays for Clinical and Preclinical
Research Applications
Lori E. Lowes
Western University
Benjamin D. Hedley
London Health Sciences Centre
Michael Keeney
Western University
Alison L. Allan
Western University
Follow this and additional works at: https://ir.lib.uwo.ca/anatomypub
Part of the Anatomy Commons, and the Cell and Developmental Biology Commons
Citation of this paper:
Lowes, Lori E.; Hedley, Benjamin D.; Keeney, Michael; and Allan, Alison L., "Adaptation of Semiautomated Circulating Tumor Cell
(CTC) Assays for Clinical and Preclinical Research Applications" (2014). Anatomy and Cell Biology Publications. 15.
https://ir.lib.uwo.ca/anatomypub/15
Journal of Visualized Experiments www.jove.com
Copyright © 2014  Journal of Visualized Experiments February 2014 |  84  | e51248 | Page 1 of 11
Video Article
Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical
and Preclinical Research Applications
Lori E. Lowes1,2, Benjamin D. Hedley3, Michael Keeney3,4, Alison L. Allan1,2,4,5
1London Regional Cancer Program, London Health Sciences Centre
2Department of Anatomy & Cell Biology, Schulich School of Medicine and Dentistry, Western University
3Special Hematology/Flow Cytometry, London Health Sciences Centre
4Lawson Health Research Institute
5Department of Oncology, Western University
Correspondence to: Alison L. Allan at alison.allan@lhsc.on.ca
URL: http://www.jove.com/video/51248
DOI: doi:10.3791/51248
Keywords: Medicine, Issue 84, Metastasis, circulating tumor cells (CTCs), CellSearch system, user defined marker characterization, in vivo,
preclinical mouse model, clinical research
Date Published: 2/28/2014
Citation: Lowes, L.E., Hedley, B.D., Keeney, M., Allan, A.L. Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and
Preclinical Research Applications. J. Vis. Exp. (84), e51248, doi:10.3791/51248 (2014).
Abstract
The majority of cancer-related deaths occur subsequent to the development of metastatic disease. This highly lethal disease stage is associated
with the presence of circulating tumor cells (CTCs). These rare cells have been demonstrated to be of clinical significance in metastatic breast,
prostate, and colorectal cancers. The current gold standard in clinical CTC detection and enumeration is the FDA-cleared CellSearch system
(CSS). This manuscript outlines the standard protocol utilized by this platform as well as two additional adapted protocols that describe the
detailed process of user-defined marker optimization for protein characterization of patient CTCs and a comparable protocol for CTC capture in
very low volumes of blood, using standard CSS reagents, for studying in vivo preclinical mouse models of metastasis. In addition, differences
in CTC quality between healthy donor blood spiked with cells from tissue culture versus patient blood samples are highlighted. Finally, several
commonly discrepant items that can lead to CTC misclassification errors are outlined. Taken together, these protocols will provide a useful
resource for users of this platform interested in preclinical and clinical research pertaining to metastasis and CTCs.
Video Link
The video component of this article can be found at http://www.jove.com/video/51248/
Introduction
In 2013 it is estimated that 580,350 individuals will die from cancer and that 1,660,290 new cases of this disease will be diagnosed in the
United States alone1. The majority of these deaths occur subsequent to the development of metastatic disease2. The current lack of effective
therapies in treating metastases and a limited understanding of the metastatic cascade makes this stage of disease highly lethal. The presence
of circulating tumor cells (CTCs) within the bloodstream have been demonstrated to correlate with metastatic disease3. These cells are extremely
rare and their detection is indicative of overall survival in metastatic breast4, prostate5, and colorectal6 cancer. In these patients, the presence
of ≥5 (breast and prostate) or ≥3 (colorectal) CTCs in 7.5 ml of blood is indicative of poorer prognosis when compared to those patients with
fewer or no detectable CTCs in the same blood volume. In addition, the change in CTC number during or after therapeutic intervention has been
demonstrated to be useful as a predictor of treatment response, often sooner than currently utilized techniques7-10.
It has been estimated that, in metastatic cancer patients, CTCs occur at a frequency of approximately 1 CTC per 105-107 blood mononuclear
cells and in patients with localized disease, this frequency may be even lower (~1 in 108). The rare nature of these cells can make it difficult
to accurately and reliably detect and analyze CTCs11. Several methods (reviewed previously12-14) have been utilized to enrich and detect
these cells by exploiting properties that differentiate them from surrounding blood components. In general, CTC enumeration is a two-part
process that requires both an enrichment step and a detection step. Traditionally, enrichment steps rely on differences in physical properties
of CTCs (cell size, density, deformability) or on protein marker expression (i.e. epithelial cell adhesion molecule [EpCAM], cytokeratin [CK]).
Following enrichment, CTC detection can be performed in a number of different ways, the most common of which are nucleic acid-based
assays and/or cytometric approaches. Each of these strategies are unique, having distinct advantages and disadvantages, however they all
lack standardization; a necessity for entrance into the clinical setting. The CellSearch system (CSS) was therefore developed to provide a
standardized method for the detection and enumeration of rare CTCs in human blood using fluorescence microscopy and antibody-based
techniques4-6. This platform is currently considered the gold standard in CTC enumeration and is the only technique approved by the U.S. Food
and Drug Administration (FDA) for use in the clinic15.
The CSS is a two component platform consisting of, (1) the CellTracks AutoPrep system (hereafter referred to as the preparation instrument),
which automates the preparation of human blood samples, and (2) the CellTracks Analyzer II (hereafter referred to as the analysis instrument),
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which scans these samples following preparation. To distinguish CTCs from contaminating leukocytes the preparation instrument employs an
antibody mediated, ferrofluid-based magnetic separation approach and differential fluorescence staining. Initially, the system labels CTCs using
anti-EpCAM antibodies conjugated to iron nanoparticles. The sample is then incubated in a magnetic field, and all unlabeled cells are aspirated.
Selected tumor cells are resuspended, and incubated in a differential fluorescence stain, consisting of fluorescently-labeled antibodies and a
nuclear staining reagent. Finally, the sample is transferred to a magnetic cartridge, called a MagNest (hereafter referred to as the magnetic
device), and scanned using the analysis instrument.
The analysis instrument is used to scan prepared samples using different fluorescence filters, each optimized to the appropriate fluorescent
particle, using a 10X objective lens. CTCs are identified as cells that are bound by anti-EpCAM, anti-pan-CK-phycoerythrin (PE) (CK8, 18, and
19), and the nuclear stain 4',6-diamidino-2-phenylindole (DAPI). Conversely, contaminating leukocytes are identified as cells that are bound by
anti-CD45-allophycocyanin (APC) and DAPI. Following scanning, computer-defined potential tumor cells are presented to the user. From these
images, the user must employ qualitative analysis using the defined parameters and differential staining discussed above to determine which
events are CTCs.
In addition to providing a standardized method for CTC enumeration, the CSS allows for molecular characterization of CTCs based on protein
markers of interest. This interrogation can be performed at the single-cell level, using a fluorescein isothiocyanate (FITC) fluorescence channel
not required for CTC identification16. Although this platform provides the capacity for molecular characterization, the detailed process of
protocol development and optimization is not well-defined. Three commercially available markers have been developed by the manufacturer
for use with the CSS, including epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and insulin-like
growth factor 1 receptor (IGF-1R). HER2 analysis, in combination with the CSS, has been utilized by several groups to illustrate the potential
for CTC characterization to inform clinical decision-making and to potentially change existing treatment guidelines. For example, Fehm et
al.17 demonstrated that approximately one third of breast cancer patients with HER2-primary tumors had HER2+ CTCs. In addition, Liu et
al.18 recently reported that up to 50% of patients with HER+ metastatic breast cancer did not have HER2+ CTCs. Herceptin, a HER2 receptor
interfering monoclonal antibody demonstrated to greatly benefit patients whose tumors express sufficient levels of HER2, is a commonly utilized
treatment for patients with HER2+ primary tumors19-21. However, these studies suggest that Herceptin may be being sub-optimally utilized
and that CTC characterization may aid in predicting treatment response. Ultimately, CTC characterization may have the potential to improve
personalized care.
CTC research is unique in that it has largely utilized a bedside-to-benchtop approach. This method, unlike benchtop-to-bedside research, which
can often take years to impact patient care, has allowed CTCs quick entry into the clinical setting. However, physicians are hesitant to use
results from CTC analysis in patient treatment decision-making due to a lack of understanding of their underlying biology. Therefore appropriate
preclinical mouse models of metastasis and complementary CTC analysis techniques must be utilized in order to investigate these outstanding
questions. In general, there are two types of preclinical models used to study the metastatic cascade, (1) spontaneous metastasis models, which
allow for the study of all the steps in the metastatic cascade, and (2) experimental metastasis models, which only allow for the study of later
steps in the metastatic process such as extravasation and secondary tumor formation22. Spontaneous metastasis models, involve tumor cell
injections into appropriate orthotopic locations (e.g. injection of prostate cancer cells into the prostate gland for the study of prostate cancer).
Cells are then given time to form primary tumors and spontaneously metastasize to secondary sites such as the bone, lung, and lymph nodes.
In contrast, experimental metastasis models involve direct injection of tumor cells into the bloodstream (e.g. via tail vein or intracardiac injection
to target cells to specific locations) and therefore skip the initial steps of intravasation and dissemination to secondary organs22. Thus far the
majority of CTC analysis in in vivo model systems has been performed using either cytometry-based23 or adapted human-based CTC techniques
(e.g. AdnaTest)24. Although useful, none of these techniques adequately reflect CTC enumeration using the gold standard CSS. Based on the
clinical approval, standardized nature, and widespread usage of the CSS, the development of a CTC capture and detection technique for in
vivo modeling that utilizes equivalent sample preparation, processing, and identification criteria would be advantageous as results would be
comparable to those obtained from patient samples. However, due to the volume requirements of the preparation instrument it is not possible to
process small volumes of blood using this automated platform. In addition, previous work by Eliane et al.25 has demonstrated that contamination
of samples with mouse epithelial cells (which also meet the standard CTC definition [EpCAM+CK+DAPI+CD45-]) can lead to misclassification of
mouse squamous epithelial cells as CTCs. To address these issues an adapted technique that allows the utilization of the CSS CTC kit reagents
combined with a manual isolation procedure was developed. The addition of a FITC labeled human leukocyte antigen (HLA) antibody to the
assay allows human tumor cells to be distinguished from mouse squamous epithelial cells.
This manuscript describes the standard, commercially developed and optimized CSS protocol for processing patient blood samples and common
pitfalls that may be encountered, including discrepant items that can lead to CTC misclassification errors. In addition, customization of the
CSS assay to examine user-defined protein characteristics of captured CTCs and a comparable adapted CSS technique that allows for the
enrichment and detection of CTCs from small volumes of blood in preclinical mouse models of metastasis are described.
Protocol
All human studies described in this manuscript were carried out under protocols approved by Western University's Human Research Ethics
Board. All Animal studies were conducted in accordance with the recommendations of the Canadian Council on Animal Care, under protocols
approved by the Western University Animal Use Subcommittee.
1. Standard CTC Enumeration from Patient Blood Samples Using the CSS
1. Human Blood Sample Collection and Preparation for Processing on the Preparation Instrument
1. Using standard aseptic phlebotomy techniques, draw a minimum of 8.0 ml of human blood into a 10 ml CellSave tube (hereafter referred to
as the CTC preservative tube), which contains ethylene diaminetetraacetic acid (EDTA) and a proprietary cellular preservative. Invert the tube
5x to prevent blood from clotting. Samples may be processed immediately or stored at room temperature for up to 96 hr.
2. Remove CSS reagents from the fridge and allow them to warm to room temperature before using.
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3. Using a disposable 10 ml pipette and automated pipettor, collect 7.5 ml of blood from the CTC preservative tube and slowly dispense blood
into an appropriately labeled preparation instrument processing tube.
4. Add 6.5 ml of dilution buffer to each sample. Mix by inverting sample 5x. Centrifuge sample at 800 x g for 10 min with the brake in the "off"
position. Follow the on-screen instructions on the preparation instrument to load all patient samples onto the system for processing. Samples
must be processed within 1 hr of preparation.
2. Control Preparation for Processing on the Preparation Instrument
1. Gently vortex the control vial and invert 5x to mix.
2. Carefully remove the cap from the control vial and place an inverted preparation instrument processing tube on top of the uncapped vial. In
one swift motion, invert the control vial, and pour the contents into the processing tube. While inverted, gently flick the sides of the control vial
to release any remaining contents.
3. Carefully remove the inverted control vial from the processing tube, ensuring that no liquid is lost and place aside. Using a 1,000 μl pipette,
collect any remaining contents from the vial and lid and gently pipette into the processing tube.
4. Follow the on-screen instructions on the preparation instrument to load the control onto the system for processing.
3. Sample Scanning on the Analysis Instrument
1. Follow the on-screen instructions on the preparation instrument to unload all samples from the system. Loosely cap each magnetic device
cartridge and tap the magnetic device using hands or lab bench to release any bubbles that are stuck to the edges of the cartridge. Once all
the bubbles have been removed, firmly cap the cartridge, lay the magnetic device flat, and incubate in the dark for at least 20 min at room
temperature. Samples must be scanned within 24 hr of preparation.
2. Turn on the analysis instrument and initialize the lamp. Once warmed (~15 min), load the system verification cartridge onto the analysis
instrument and select the QC Test tab. Follow the on-screen instructions to perform the necessary quality control measures.
3. Load a sample onto the analysis instrument and select the Patient Test tab. All saved information from the preparation instrument will be
displayed. Click Start to initialize sample scanning. The system will perform a coarse focus and edge detection on the magnetic device
cartridge.
4. Adjust all edges as necessary using the directional keys. Select Accept. The system will perform a fine focus and begin sample scanning.
5. Following control scanning the results should be validated using the defined criteria for cells spiked at high (CK+DAPI+CD45-APC+) and low
(CK+DAPI+CD45-FITC+) concentrations. Following patient sample scanning the results should be reviewed for captured CTCs using the
defined CTC criteria (CK+DAPI+CD45-).
2. CTC Characterization for User-defined Markers using the CSS
1. Preparation of User-defined Markers and Instrument Initialization
1. Dilute the antibody of interest using Bond Primary Antibody Diluent to the desired concentration in a marker reagent cup using the following
formula, where the working concentration is the concentration of the antibody after addition to the sample and the stock concentration is the
concentration of antibody in the reagent cup. For multiple samples, adjust the antibody volumes as described in Table 1. Place the marker
reagent cup into position 1 in the reagent cartridge and load the cartridge onto CSS.
 
Stock Concentration = (Working Concentration x 850 μl) / 150 μl
 
2. Collect blood, prepare samples, and load the preparation instrument as described in the above Standard CTC Enumeration from Patient
Blood Samples using the CSS protocol. To enable custom marker addition, select User Defined Assay when prompted by the preparation
instrument. Input the marker name and select Save. As samples are loaded onto the instrument, the operator will be prompted to indicate
which should receive custom marker by selecting Yes or No as necessary.
2. Sample Scanning of User-Defined Markers on the Analysis Instrument
1. Turn on the analysis instrument, initialize the lamp, and perform quality control and system verification as described in Section 3.2 of the
Standard CTC Enumeration from Patient Blood Samples using the CSS protocol.
2. Load a sample onto the analysis instrument and select the Setup tab. To initialize the FITC channel, select CellSearch CTC as the Kit ID
under the Test Protocols section. From this menu, select CTC Research, click the Edit button and set the exposure time as desired. It is
recommended that an exposure time of 1.0 sec not be exceeded when using the CSS CTC kit as this can increase bleed-through into other
fluorescent channels utilized for CTC identification.
3. Adaptation of the Standard CSSProtocol for use in Preclinical Mouse Models
**Adapted from Veridex Mouse/Rat CellCapture Kit (no longer commercially available)
1. Mouse Blood Collection and Storage
1. Prior to blood collection, run ~30 μl of 0.5 M EDTA back and forth through a 22 G needle, leaving a small amount of EDTA in the hub.
2. Collect a minimum of 50 μl of mouse blood from mice previously injected with human tumor cells via orthotopic, tail vein, or intracardiac
routes. Collect blood from the saphenous vein (for serial CTC analysis) or by cardiac puncture (for terminal CTC analysis). Remove needle
and dispense blood into a 1 ml EDTA microtainer blood collection tube. Mix by inversion or gently flick tube to prevent blood from clotting.
Blood may be processed immediately or stored at room temperature for up to 48 hr following the addition of an equal volume of CytoChex
cellular preservative.
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2. CTC Enrichment
1. Remove CSS reagents from the fridge and allow them to warm to room temperature before using.
2. Transfer the equivalent of 50 μl of whole blood to a 12 mm x 75 mm flow cytometry tube. Add 500 μl of dilution buffer to each sample,
washing down any blood that remains on the sides of the tube. If necessary, a short centrifuge spin can be used to collect any remaining
blood.
3. Gently vortex the anti-EpCAM ferrofluid and add 25 μl to each sample by placing the tip of the pipette directly into the sample. Add 25 μl of
Capture Enhancement reagent and vortex gently to mix. Incubate samples at room temperature for 15 min.
4. Place sample tubes into the magnet and incubate for 10 min. While the sample tubes are still in the magnet, use a glass pipette to carefully
aspirate the residual liquid without touching the wall of the tube next to the magnet and discard.
3. CTC Staining
1. Remove the sample tubes from the magnet and resuspend in 50 μl of Nucleic Acid Dye, 50 μl of Staining Reagent, 1.5 μl of anti-mouse
CD45-APC, 5.0 μl of anti-human HLA-Alexa Fluor 488, and 100 μl of Permeabilization Reagent. For multiple samples, these reagents may be
premixed and 206.5 μl of mixture may be added to each tube. Vortex gently to mix and incubate for 20 min at room temperature in the dark.
2. Add 500 μl of dilution buffer, vortex gently, place sample tubes into the magnet, and incubate for 10 min. While the sample tubes are still in
the magnet, use a glass pipette to carefully aspirate the residual liquid without touching the wall of the tube next to the magnet and discard.
Remove the sample tubes from the magnet and resuspend in 350 μl of dilution buffer. Vortex gently to mix.
4. Magnetic Device Loading
1. Using a gel loading tip, carefully transfer the entire volume from the sample tube into a cartridge in the magnetic device. Start at the bottom of
the cartridge and slowly withdraw the tip as the sample is dispensed.
2. Once the entire sample has been transferred, loosely cap the magnetic device cartridge and tap the magnetic device using hands or lab
bench to release any bubbles that are stuck to the edges of the cartridge as described in Section 3.1 of the Standard CTC Enumeration
from Patient Blood Samples using the CSS.
3. Pop any bubbles using a sterile 22 G needle by trapping them between the bevel and the edge of the cartridge. Once all the bubbles have
been removed, firmly cap the cartridge, lay the magnetic device flat, and incubate in the dark for at least 10 min. Samples must be scanned
within 24 hr of preparation.
5. Scanning of Manually Separated Samples on the Analysis Instrument
1. Turn on the analysis instrument, initialize the lamp, and perform quality control and system verification as described in Section 3.2 of the
Standard CTC Enumeration from Patient Blood Samples using the CSS protocol.
2. Load the sample onto the analysis instrument and select the Setup tab. Clear any existing data on the magnetic device data button by
clicking the Format Sample button. Enable the FITC channel and set the exposure time to 1.0 sec as described in Section 2.2 of the CTC
Characterization for User-Defined Markers using the CSS.
3. Click on the Patient Test tab and select Edit to input the sample information. Select CellSearch CTC as the Kit ID and CTC Research as the
Test Protocol. Input the remaining necessary information as indicated as the asterisk. Save the sample information and click Start.
Representative Results
Standard CTC Enumeration Assay
The sensitivity and specificity of the CSS has been well documented in the literature. However, to validate equivalent CTC recovery, spiked
(1,000 LNCaP human prostate cancer cells) and unspiked human blood samples from healthy volunteer donors were processed on the CSS
using the standard CSSCTC protocol. As expected, unspiked samples were free of CTCs, 0.00±0.00%, and CTC recovery was demonstrated
to be 86.9±4.71% for spiked samples (Figure 1A). CSS gallery images obtained from spiked samples were of optimal quality and CTCs were
easy to distinguish from non-CTCs. However, when processing samples obtained from cancer patients, identification of CTCs is slightly more
challenging, with many cells appearing smaller in size and being less easily distinguishable from non-CTCs (Figure 1B). In addition, when
reviewing patient samples 6 categories of events were identified that were commonly discrepant items between reviewers (Figure 1C). These
6 categories included, (1) small events that did not meet the 4 µm size requirement for CTC classification; (2) items with dim CK and/or DAPI
staining; (3) justified (should be counted as a CTC) versus unjustified (should not be counted as a CTC) bleed through into the CD45-APC
channel caused by bright CK-PE staining; (4) FITC+ events; (5) pixelated images in the CK and/or DAPI channels; and (6) events with DAPI
staining that is larger than CK images or those with DAPI staining that does not overlap >50% with the CK image. For categories (2) and
(5) specific criteria exist for CTC classification. For category (2), items with dim CK/DAPI can be classified as CTCs provided that an intact
membrane can be observed in the CK channel and an appropriately sized DAPI image is noted. For category (5), items with pixelated CK/DAPI
cannot be classified as CTCs if any pixelation is observed in the CK channel. However, pixelation is acceptable in the DAPI channel provided
that it is not too severe (i.e. image is entirely white on a background, no grey areas - described by Janssen Diagnostics (formerly Veridex) as
white paint on a black background) or diffuse (must still appear oval in shape and fit within the CK).
User-Defined Marker Assay Development
Adaptation of the CSS to characterize CTCs for user-defined markers requires significant work-up with rigorous controls and has been described
previously16. As a general rule, appropriate optimization of any user-defined marker requires that negative controls be employed to ensure that
results are specific. The best results are obtained when spiked samples are processed with both a nonspecific IgG control in place of the target
antibody and with the antibody diluent alone as described previously. Various target antibody concentrations and exposure times should also be
assessed and validated using cell lines with high, low, and absent (negative) antigen densities. Optimal protocol conditions are achieved when
the assay demonstrates both high sensitivity for the target antigen and low background noise from nonspecific binding16.
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An example of this work-up using a cancer stem cell marker, CD44, is presented here. Initial testing with this marker began using the standard
CSS CTC kit (hereafter referred to as the traditional CTC kit), which utilizes the FITC channel for user-defined marker development. Using the
traditional CTC kit, it was demonstrated that, after significant optimization, the maximum number of CTCs that could be classified as CD44+
was 69.3±2.67% using samples spiked with 1,000 MDA-MB-468 human breast cancer cells, known to demonstrate high CD44 expression
with the majority of cells (98.4±0.90%; as determined by flow cytometry) expressing this protein (Figure 2A). Based upon these findings it was
hypothesized that the commercially available CSS CXC kit might produce improved results. This kit allows for improved visualization of markers
with a lower antigen density (~50,000 antigens/cell) compared with the traditional CTC kit (optimized for markers with a density of ~100,000
antigens/cell) by reversing the fluorescence channel in which the CK8/18/19 (traditionally represented in the PE channel) and the user's marker
of interest (traditionally represented in the FITC channel) are represented (therefore hereafter the CXC kit will be referred to as the low antigen
density CTC kit)26. After significant optimization, it was demonstrated that this change allowed for improved CD44 staining, with 98.8±0.51% of
CTCs classified as CD44+ using CD44-PE at a concentration of 1.0 µg/ml and an exposure time of 0.6 sec (Figure 2A). Appropriate optimization
of any user-defined marker also requires validation using high antigen density (MDA-MB-468), low antigen density (21 NT), and negative
(LNCaPs) cell lines for the marker of interest (Figure 2B).
CTC Analysis in Preclinical Mouse Models
To determine the sensitivity and specificity of the adapted mouse CSS protocol, spiked (1,000 LNCaP human prostate cancer cells) and
unspiked mouse blood samples were processed manually and scanned on the analysis instrument and compared to results obtained using
the same cell line processed using the standard automated CSS protocol on the preparation instrument (Figure 3A). As expected, unspiked
samples were free of CTCs using both assays, 0.00±0.00% and CTC recovery using the adapted mouse kit (90.8±5.18%) was not significantly
different from results obtained using the standard automated system (86.9±4.71%; p > 0.05). Images obtained using the manual mouse adapted
protocol did not differ from those observed using the standard automated technique, with the exception of the addition of the HLA-FITC marker.
In addition, mouse squamous epithelial cells do not stain positively for HLA-FITC (Figure 3B). To confirm that this technique was as sensitive as
the standard CSS protocol for the isolation of low number of CTCs, serial dilutions were performed with spiked blood samples and the correlation
of expected number of cells versus recovered number of cells was assessed (Figure 3C). Results demonstrate that CTCs could effectively be
recovered down to a sensitivity of 5 cells/50 µl of whole blood using this assay. These values correlated with expected results with an r2 = 0.99.
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Figure 1. CTC enumeration and interpretation using the standard CSS protocol. (A) CTC recovery measured as a percentage of the
number of spiked cells. Cells were counted by hemocytometer and ~1,000 LNCaP human prostate cancer cells were spiked into 7.5 ml of human
blood. Unspiked human blood samples were used as a negative control (n = 3). Data are presented as the mean ± SEM. (B) Representative
CSS gallery images of the differences in CTC quality observed in spiked blood samples (i.e. healthy donor blood spiked with tumor cells from
culture) versus samples collected from cancer patients. (C) Representative CSS gallery images of commonly discrepant items that are often
misclassified. Orange squares indicate acceptable CTCs, identified as CK+/DAPI+/CD45-. Images acquired at 10X objective magnification. Click
here to view larger image.
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Figure 2. Characterization of CTCs for user-defined markers using the CSS. (A) Percentage of cells classified as CD44+ using the CTC and
CXC kits on the CSS (n = 3). Data are presented as the mean ± SEM. *** = significantly different (P < 0.0005). (B) Representative CSS gallery
images of blood from a healthy volunteer donor (7.5 ml), spiked with ~1,000 cells from the identified cell line, incubated with 1.5 µg/ml of anti-
CD44-PE, and scanned at an exposure time of 0.2 sec. Orange squares indicate CD44+ CTCs, identified as CK+/DAPI+/CD45-/CD44-PE+. Click
here to view larger image.
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Figure 3. Adaptation of the CSS procedure for use in preclinical mouse models of metastasis. (A) CTC recovery using the adapted
mouse CSS protocol measured as a percentage of the number of spiked cells and compared to results obtained using the standard human
CSS protocol. Cells were counted by hemocytometer and ~1,000 LNCaP human prostate cancer cells were spiked into 7.5 ml of human blood.
Unspiked human blood samples were used as a negative control (n = 3). Data are presented as the mean ± SEM. ns = not significant. (B)
Representative CSS gallery images of CTCs captured the adapted mouse CSS protocol demonstrating that HLA-AF488 is able to distinguish
human from mouse cells. (C) Analysis of correlation and linear regression of the expected versus recovered number of spiked tumor cells at
various concentrations. LNCaP human prostate cancer cells were initially counted by hemocytometer and subsequently spiked into mouse blood
at a concentration of ~1,000 tumor cells/50 µl of blood. Spiked mouse blood was then serially diluted to a concentration of 5 tumor cells/50 µl and
processed using the mouse adapted CSS protocol (n = 3). Click here to view larger image.
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# of Samples with User Defined Marker Added Total Volume to Add to Reagent Cup (µl)
1 450
2 600
3 750
4 900
5 1,050
6 1,200
7 1,350
8 1,500
Table 1. Total volume requirements for the CSS when processing various numbers of samples with a user-defined marker. **Adapted
from Veridex White Paper (available at: http://www.veridex.com/pdf/CXC_Application_Guideline.PDF).
Discussion
Despite the development of many new CTC technologies since the introduction of the CSS in 2004, this technique is still the only clinically
approved technology on the market today and therefore it is considered the current gold standard for CTC detection and enumeration. This
manuscript has demonstrated that although the CSS has rigorous quality control standards it can be subject to interpretation bias and that
CTC identification in patient samples is much different from identification in spiked samples. Six categories of commonly discrepant items were
identified that can cause CTC misclassifications to occur. These discrepant items highlight the need for multiple reviewers on each patient
sample processed on this instrument. In addition, the differences observed in spiked versus patient obtained CTCs demonstrates that there
is a necessity for any new CTC technologies to be validated in both spiked and patient samples. In addition, these new technologies must be
compared to the gold standard CSS using split sample testing of both spiked and patient samples, as efficient CTC capture from spiked samples
only does not necessarily reflect CTC capture efficiency in patient samples.
Although the CSS has the capability to perform characterization of captured CTCs, it is quite restricted with regards to highly customizable
optimization. In general, the only parameters that can be changed on this instrument for optimization of user-defined markers are the antibody
concentration and the length of time that the fluorophore is exposed to the mercury lamp. This limited capacity for optimization can present
problems when working-up user-defined markers on the CSS. One solution proposed in this manuscript (described in detail previously16) is the
use of the low antigen density CTC kit which switches the FITC and PE fluorescent channels allowing for better visualization of markers with a
low antigen density. Regardless of which kit is utilized (traditional- or low antigen density CTC kit) there are several necessary steps that must
be undertaken to ensure appropriate marker sensitivity, specificity, and optimization. Firstly, assay sensitivity must be assessed in comparison
to a well validated method, such as flow cytometry, that will allow determination of the expected detection level (i.e. the percentage of cells in
the cell population that express the marker of interest) of the user-defined marker. Secondly, the assay must be assessed for its ability to detect
the marker of interest in cell lines with various levels of expression (i.e. high and low antigen densities) and its specificity must be validated in
a cell line that is negative for the marker of interest. In all cases, all cell lines must be tested using a cells only control (no antibody added), the
appropriate IgG control, and the antibody of interest at various concentrations and exposure times to determine the most appropriate settings
that will ensure optimization of the user-defined marker. However, it should be noted that although characterization of CTCs is possible on the
CSS, currently only one user-defined marker of interest can be explored in each sample, and that the system is very limited with regards to
downstream applications due to the harsh processing of the samples.
The unique bedside-to-benchtop approach utilized in CTC research has allowed for quick entry of this useful assay into the clinical setting.
However, it has resulted in an inadequate understanding of the basic biology of these rare cells. Therefore the development and optimization
of assays that allow for assessment of CTCs in preclinical in vivo mouse models of cancer are needed. This manuscript describes an adapted
CSS protocol that allows for CTCs to be assessed in 50 µl volumes of mouse blood, ideally suited for serial CTC collection experimental models.
This manuscript demonstrates that CTC enumeration using this protocol is comparable to results obtained using the CSS in combination with
the traditional CTC kit, with no significant differences in CTC capture efficiency between the automated and manual separation techniques. In
addition, during the development of this assay it was recognized, as previously described in the literature25, that mouse squamous epithelial
cell contamination can make accurate identification of CTCs more difficult and sometimes impossible. Therefore to combat this issue a user-
defined HLA-Alexa Fluor 488 was added to this protocol to ensure that only human cells (CK+DAPI+CD45-HLA-Alexa Fluor 488+) are being
appropriately assigned as CTCs. It is important to note that the LNCaP cell line used in this manuscript is HLAlow and therefore HLA-Alexa
Fluor 488 may need to be titrated for cell lines with varying HLA expression. Although we have added an HLA-Alexa Fluor 488 to our protocol
to ensure accurate identification of CTCs, it is noteworthy that the vast majority of mouse squamous epithelial cells were easily identifiable by
morphology and were limited in cell number (0.33±0.24 events/50 µl; n = 9). Higher cell numbers (up to 11 events/50 µl) were only observed
when blood collection (via cardiac puncture) proved difficult and repeated attempts were necessary. Therefore we propose that if desired, on-
system characterization of CTCs could be accomplished by omitting this marker. In addition, although not described here, we anticipate that
collection of CTCs and further downstream characterization of CTCs using other methods could be easily achieved as demonstrated previously
using the CSS27,28.
Although the CSS has been utilized clinically to effectively detect CTCs in the blood of metastatic breast, prostate and colorectal cancer
patients4,10,29, it does have several limitations. In up to 35% of patients with various metastatic cancers, CTCs are undetectable despite the
presence of widespread systemic disease30. This lack of detection has been proposed to be as a result of the epithelial-to-mesenchymal
transition, a well-documented process known to enhance cancer invasion, metastasis, and overall aggressiveness31. This transition has been
associated with a significant reduction in epithelial markers, such as EpCAM, and a corresponding increase in mesenchymal markers32. Several
studies have recently demonstrated that the presence of these mesenchymal markers in CTCs are indicative of poorer prognosis and that many
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of these cells lack expression of epithelial markers that would be necessary for their detection using the CSS24,33-38. This suggests that the
standard CSS definition may be missing some of the most aggressive CTCs.
Despite the described limitations, it is anticipated the protocols described in this manuscript will be important tools for improved CTC analysis
using the CSS, development of novel CTC technologies, optimization of user-defined markers, and improved understanding of CTC biology
using in vivo preclinical mouse models. Taken together, these protocols will provide a useful resource for users of this platform interested in
preclinical and clinical research pertaining to metastasis and CTCs.
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